News from csl behring A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 30, 2015, 08:58 ET
CSL Behring logo.

European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients

rIX-FP Regulatory Submissions Now Made in EU and U.S.; Underscores CSL Behring's Legacy of Improving the Care for Patients with Bleeding...

Mar 17, 2015, 09:00 ET

The Lancet Publishes CSL Behring's Kcentra® Phase III Data

CSL Behring today announced that The Lancet has published results from a Phase III clinical study showing Kcentra® (Prothrombin Complex...

Mar 09, 2015, 09:00 ET
CSL Behring employees take time out from their work day to package clothes, shoes, books, toys, baby safety equipment and school supplies for thousands of children in the Philadelphia area as part of the Cradles to Crayons program. Cradles to Crayons is one of many charitable programs supported by CSL Behring and its employees throughout the year.

CSL Behring to Provide $80,000 in Scholarship Funding For Low-Income Students in Philadelphia Area

CSL Behring announced that it is partnering with Children's Scholarship Fund Philadelphia (CSFP) to support scholarships for low-income students....

Feb 27, 2015, 09:00 ET
CSL Behring logo

CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia

 In recognition of Rare Disease Day and as part of its ongoing commitment to the global bleeding disorders community, CSL Behring announced...

Feb 04, 2015, 11:00 ET
CSL Behring logo

U.S. FDA Accepts for Review CSL Behring's Biologics License Application for rIX-FP for Hemophilia B Patients

CSL Behring Achieves Another Key Milestone in PROLONG-9FP, its Recombinant Factor IX Fusion Protein Development Program; Continues to Advance CSL...

Feb 02, 2015, 09:00 ET

FDA Approves New Dosing Option for CSL Behring's Hizentra®

 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has expanded the administration options...

Dec 22, 2014, 13:30 ET
Dec 16, 2014, 09:04 ET
CSL Behring logo.

CSL Behring Submits Biologics License Application for FDA Approval of Recombinant Fusion Protein Linking Coagulation Factor IX with Recombinant Albumin (rIX-FP) for Hemophilia B Patients

CSL Behring Continues Improving Patient Well-Being; Key Milestone Achieved in PROLONG-9FP, Company's Recombinant Factor IX Fusion Protein...

Dec 04, 2014, 09:00 ET
CSL Behring logo.

CSL Issues "Our Corporate Responsibility 2014" Report

CSL Behring's parent company CSL Limited (ASX: CSL) has issued its annual corporate responsibility report – "Our Corporate Responsibility...

Dec 04, 2014, 06:00 ET

La EMA aprueba la ficha técnica enmendada de Hizentra® de CSL Behring

-- La nueva ficha técnica ofrece una mayor flexibilidad y capacidad para personalizar la dosificación CSL Behring ha...

Dec 04, 2014, 06:00 ET

EMA approva la revisione del Riassunto delle Caratteristiche del Prodotto (RCP) Hizentra® di CSL Behring

-- Il nuovo RCP favorisce maggiore flessibilità e capacità di personalizzare il dosaggio  CSL Behring ha annunciato...

Dec 04, 2014, 06:00 ET

EMA erteilt Zulassung für aktualisierte Produktinformation für Hizentra® von CSL Behring

-- Neue Produktinformation unterstützt größere Flexibilität und die Möglichkeit zur individuellen Dosierung...

Dec 01, 2014, 11:00 ET

CMS Extends New Technology Add-On Payment for CSL Behring's Kcentra®

CSL Behring today announced that the Centers for Medicare and Medicaid Services (CMS) has extended the new technology add-on payment...

Nov 17, 2014, 13:18 ET

Neue Daten beim 16. Biennial Meeting der European Society for Immunodeficiencies (ESID) sprechen für individualisierte Dosierung von Hizentra®

-- Flexible Dosierungsschemata und Push-Applikation stehen im Fokus der Präsentationen  Das Behandlungsziel der...

Nov 03, 2014, 15:29 ET

En la 16 Reunión Bienal de la Sociedad Europea para Inmunodeficiencias se respalda dosis individualizada con Hizentra®

- Evidencia presentada en la 16 Reunión Bienal de la Sociedad Europea para Inmunodeficiencias: (ESID) que respalda la dosis...

Nov 03, 2014, 14:27 ET

La testimonianza presentata al 16esimo Congresso Biennale della European Society for Immunodeficiencies (ESID) supporta il dosaggio individualizzato con Hizentra®

-- Le presentazioni pongono l'attenzione sui regimi di dosaggio flessibili di Hizentra e sulla modalità di somministrazione push...

Oct 31, 2014, 08:30 ET
CSL Behring logo

Evidence presented at the 16th Biennial Meeting of the European Society for Immunodeficiencies (ESID) Supports Individualized Dosing with Hizentra®

The goal of individualized therapy in the treatment of primary immunodeficiency (PI), a serious, life-threatening and lifelong condition, is to...

Oct 29, 2014, 11:57 ET

CSL Behring signe un accord de développement stratégique auprès d'Enable Injections afin de commercialiser un tout nouveau dispositif de délivrance médicamenteuse

CSL Behring a annoncé aujourd'hui que sa filiale CSL Behring AG, basée à Berne, en Suisse, et Enable Injections, LLC, basée...

Oct 29, 2014, 10:02 ET

CSL Behring y Enable Injections lanzan un nuevo dispositivo de administración de medicamento

-- CSL Behring firma un acuerdo de desarrollo estratégico con Enable Injections para comercializar un nuevo dispositivo de...

Oct 29, 2014, 10:00 ET
Professional golfer Perry Parker with this year's golf winner and alumni from the program

CSL Behring Announces Winners of its 13th Annual Gettin' in the Game(SM) Junior National Championship Program

 CSL Behring announced that William McCarthy from the Western Pennsylvania Chapter of the National Hemophilia Foundation and Nicholas Cleghorn...